Such TKFs characterize a group of hematological disorders, sharing similar clinico-pathological features, such as peripheral blood eosinophilia, clinical presentation as MPN and/or lymphoid tumors, and, at least for PDGFRα and PDGFRβ fusions, good response to Imatinib. This evidence concerns the gene PDGFRA and lymphoid neoplasm.